Chikungunya is a mosquito-borne disease that leaves the afflicted patient with incapacitating arthritis that can last for several months or even years.1 Since the start of the largest ever outbreak of chikungunya virus infecton in 2005 in the Indian Ocean, there has been a resurgence in chikungunya cases that continues to this day.1 Adaptation of chikungunya virus to the globally distributed Asian tiger mosquito (Aedes albopictus) has led to autochthonous cases in both Europe and the Americas.2 In the year after chikungunya virus first appeared in the Caribbean, an estimated 1 million cases were reported, with concerns that the virus could spread extensively throughout the Americas.3 Despite the emerging importance of chikungunya virus, no specific treatment or vaccine is available for infected individuals. In The Lancet Infectious Diseases, Katrin Ramsauer and colleagues4 report promising results from a randomised, phase 1, active-comparator trial assessing the immunogenicity, safety, and tolerability of a live recombinant measles-virus-based chikungunya vaccine.